Embla Medical hf マネジメント

マネジメント基準チェック /34

Embla Medical hfの CEO はSveinn Solvasonで、 Apr2022年に任命され、の在任期間は 2.58年です。の年間総報酬は$ 1.18Mで、 48.8%給与と51.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.016%を直接所有しており、その価値はDKK 2.45M 。経営陣と取締役会の平均在任期間はそれぞれ2.6年と15.8年です。

主要情報

Sveinn Solvason

最高経営責任者

US$1.2m

報酬総額

CEO給与比率	48.8%
CEO在任期間	2.6yrs
CEOの所有権	0.02%
経営陣の平均在職期間	2.6yrs
取締役会の平均在任期間	15.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Embla Medical hf の収益と比較して、Sveinn Solvason の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	US$69m
Jun 30 2024	n/a	n/a	US$61m
Mar 31 2024	n/a	n/a	US$57m
Dec 31 2023	US$1m	US$576k	US$58m
Sep 30 2023	n/a	n/a	US$52m
Jun 30 2023	n/a	n/a	US$45m
Mar 31 2023	n/a	n/a	US$43m
Dec 31 2022	US$780k	US$409k	US$43m

報酬と市場: Sveinnの総報酬 ($USD 1.18M ) は、 UK市場 ($USD 2.07M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Sveinnの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Sveinn Solvason (46 yo)

2.6yrs

在職期間

US$1,180,000

報酬

Mr. Sveinn Solvason had been Chief Financial Officer of Embla Medical hf. (formerly known as ssur hf.) since May 2013 until April 1, 2022 and serves as its President & CEO since April 1, 2022.Mr. Solvaso...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sveinn Solvason	President & CEO	2.6yrs	US$1.18m	0.016% DKK 2.5m
Ossur Kristinsson	Founder	no data	US$25.00k	データなし
Gudny Sveinsdottir	Chief Financial Officer	2.2yrs	データなし	データなし
Lukas Marklin	Chief Operating Officer	1.4yrs	データなし	データなし
Edda Luovigsdottir	Investor Relations Director	no data	データなし	データなし
Margret Fridriksdottir	Executive Vice President of People	no data	US$242.00k	0.0083% DKK 1.3m
Olafur Gylfason	Chief Commercial Officer	no data	US$600.00k	0.0030% DKK 459.8k
Gudjon Karason	Executive Vice President of EMEA & APAC	7yrs	データなし	0.023% DKK 3.5m
Christian Robinson	President of Americas	no data	データなし	0.0031% DKK 473.6k
Hildur Einarsdottir	Executive Vice President of Research & Development	2.6yrs	データなし	0.00014% DKK 21.5k

2.6yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: 0FIWの経営陣は経験豊富であると考えられます ( 2.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Niels Jacobsen	Chairman of the Board	19.8yrs	US$108.00k	0.048% DKK 7.3m
Svafa Gronfeldt	Vice Chairman of the Board	16.8yrs	US$72.00k	データなし
Gudbjorg Eggertsdottir	Independent Director	11.7yrs	US$43.00k	0.0062% DKK 944.1k
Arne Nielsen	Director	15.8yrs	US$50.00k	データなし
Alberto Esquenazi	Independent Director	3.7yrs	US$43.00k	データなし

15.8yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: 0FIWの取締役会は経験豊富で経験豊富です ( 15.8年の平均在任期間)。

Embla Medical hf マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Less than half of directors are independent

Recent updates

Investor sentiment improves as stock rises 18%

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

Less than half of directors are independent

Less than half of directors are independent

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Less than half of directors are independent

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

Less than half of directors are independent

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Less than half of directors are independent

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: US$0.14 (vs US$0.10 in FY 2022)

Össur hf. Provides Earnings Guidance for the Year 2024

Less than half of directors are independent

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Össur hf., Annual General Meeting, Mar 12, 2025

Less than half of directors are independent

Össur hf. Reaffirms Financial Guidance for the Year 2023

Less than half of directors are independent

Össur hf. Announces Executive Changes

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Less than half of directors are independent

Less than half of directors are independent

Össur hf. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Less than half of directors are independent

Össur hf. to Report Q1, 2023 Results on Apr 25, 2023

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: US$0.016 (vs US$0.041 in 3Q 2021)

Less than half of directors are independent

Össur hf. (CPSE:OSSR) acquired Naked Prosthetics.

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: US$0.034 (vs US$0.046 in 2Q 2021)

Össur hf. Revises Earnings Guidance for the Year 2022

Össur hf. Reports Preliminary Earnings Results for the Second Quarter and First Half of 2022

Less than half of directors are independent

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Össur Hf. Announces New R&D Leadership

Less than half of directors are independent

Össur Launches New POWER KNEE

Össur hf. Announces Sales Guidance for the Full Year 2022

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Össur Hf. Announces Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$0.027 (vs US$0.017 in 1Q 2020)

Össur Hf. Provides Financial Guidance for the Full Year 2021

Vice Chairman Kristján Ragnarsson has left the company

Full year 2020 earnings released: EPS US$0.015 (vs US$0.16 in FY 2019)

Revenue misses expectations

Össur hf., Annual General Meeting, Mar 08, 2022

Laboratoires Innothera S.A.S completed the acquisition of Gibaud SAS from Össur hf. (CPSE:OSSR).

Össur Hf. Withdraw Its Financial Guidance for 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34